CMS Takes A Look At Alzheimer’s With Lilly's Amyvid In Mind

The Alzheimer’s drug Amyvid received FDA approval for a narrower indication than the sponsors originally wanted. The limited indication got the imaging agent to market, but now Amyvid faces another challenge on the reimbursement front.